Effective therapeutic options for such aggressive cancers represent a significant unmet medical need.
Understanding what triggers the change from treatable to resistant cancers and how these aggressive cancers spread, evade the immune system, and acquire drug resistance is a major health issue.
Since our foundation, BerGenBio has developed and applied proprietary technologies to better understand the biological drivers of these aggressive cancer cells and to discover and develop novel drugs for treating patients with these cancers.
Using our CellSelect™ platform technology, we have validated a key target on tumour cells called AXL kinase that mediates the transformation of cancer cells into their aggressive form. This process is called the epithelial-mesenchymal transition (EMT).
We have protected this understanding with intellectual property rights and are developing first-in-class selective AXL kinase inhibitor drugs and companion diagnostics. We are progressing our lead drug candidate, BGB324 in human clinical trials in multiple cancer indications.